Glycomic Therapeutics Market Scope And Analysis

Report Code : TIPRE00029576
Category : Pharmaceuticals

Status : Published
No. of Pages : 330

Buy Now

Glycomic Therapeutics Market Scope, Growth, Size and Share by 2028

Buy Now

Glycomic Therapeutics Market Report Scope

Report Attribute	Details
Market size in 2021	US$ 99.02 Billion
Market Size by 2028	US$ 257.58 Billion
Global CAGR (2021 - 2028)	15.8%
Historical Data	2019-2020
Forecast period	2022-2028
Segments Covered	By Class Isolated and Synthetic By Structures Glycoproteins Targeting Sialic Acid Proteoglycans Targeting Glycosaminoglycans Glycosylphosphatidylinositol-Anchored Proteins & Heparin Based Glycans Targeting Glycosphingolipids By Indications Thrombosis & Chemoprophylaxis Anaemia Anti-Adhesive & Anti-Inflammatory Cataracts Gaucher By Mode of Action Inhibits Neuraminidase Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate Erythropoietin & Enzyme Replacement Therapy
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Intellihep Ltd Protalix Biotherapeutics BioMarin Pharmaceutical Inc Genzyme Corporation Sanofi Halozyme Therapeutics Inc Bayer AG Alzheon Inc GlycoMar GlaxoSmithKline plc

Mode of Action-Based Insights

Based on mode of action, the glycomic therapeutics market is segmented into inhibits neuraminidase; inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate; erythropoietin & enzyme replacement therapy (ERT); tissue plasminogen activator; inhibits glucosylceramide synthase; interleukin 1, 2 & 3; beta & gamma interferons; and others. In 2021, the erythropoietin & enzyme replacement therapy (ERT) segment held the largest share of the market. However, the inhibits neuraminidase segment is expected to register the highest CAGR during the forecast period.

Intellihep Ltd; Protalix Biotherapeutics; BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Halozyme Therapeutics, Inc.; Bayer AG; Alzheon, Inc.; GlycoMar; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd are among the leading players operating in the glycomic therapeutics market. These companies have been implementing various strategies that have helped their growth, resulting in several developments in the market.